Cambridge woos drug discovery company
The burgeoning Cambridge biotech cluster has claimed another new convert.Lectus Therapeutics Ltd, the drug discovery and development company focusing on next-generation ion channel modulators, is relocating its entire corporate headquarters and research facility to the Babraham Research Campus.
Lectus, originally based in Bristol, will run all research operations as well as commercial and financial activities from the new base.
Lectus’ relocation to Cambridge forms an important part of its strategy in developing a robust infrastructure to reflect the growth of its research and development activities following a successful £8.2m Series A financing announced earlier this year.
The company has been operating part of its research activities at Babraham since April, following its acquisition of NeuroServe Limited, an electrophysiology company providing research facilities important in the development of Lectus’ ion channel modulators.
Lectus has now taken steps to integrate its entire commercial and research activities, including the exploitation of its proprietary proteomics research engine, LEPTICS®, to the Cambridge biotechnology cluster.
CEO Dr Roland Kozlowski, said: “Lectus’ move to the new facility at the Babraham Research Campus represents the next step in the implementation of our strategy for growth.
“With this move, we will benefit from improved research facilities and exceptional local infrastructure and will be in an excellent position to progress our next-generation ion channel drugs, for treatment of pain and urinary incontinence, towards the clinic.”
Lectus, incorporated at the end of 2002, specialises in the discovery and development of novel drugs for diseases associated with pain management, urinary incontinence and angina.